Treatment benefits and outcome determinants in (neo)adjuvant trials - memoinOncology
Stephen V Liu, MD on Twitter: "#ASCO22 Discussion of PEARLS (KEYNOTE-091, @ETOP_eu 8-15), a phase III study of adjuvant pembrolizumab in resected NSCLC. The study did meet its primary endpoint (DFS HR
KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement In Disease-Free Survival Versus Placebo As Adjuvant Treatment For Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless Of PD-L1 Expression 2023 - EORTC
IJMS | Free Full-Text | Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials
Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to
2022ESMO精彩研究抢先看（附摘要下载） - 知乎
Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ on Twitter: "🚨 Adjuvant pembrolizumab for early-stage NSCLC following complete resection: the ph III PEARLS(KEYNOTE-091) by Luis Paz Ares @ETOP_eu @EORTC #LCSM Primary endpoint: DSF in overall population and PDL1
Stephen V Liu, MD on Twitter: "#ASCO22 While PEARLS did meet its endpoint, we already have atezolizumab approved in this space after IMpower 010. Notes differences between these trials and again -
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial - The Lancet Oncology
Erfolg mit Pembrolizumab als Adjuvans bei reseziertem NSCLC | springermedizin.de
Lancet Oncol：派姆单抗辅助治疗可显著延长术后IB-IIIA期NSCLC患者的生存期-MedSci.cn
KEYNOTE-091 and IMPOWER010: adjuvant chemotherapy for NSCLC - YouTube
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial - The Lancet Oncology
نشرة_أخبار_الأورام | Facebook
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial | AIOM
Stephen V Liu, MD on Twitter: "#ASCO22 Discussion of PEARLS (KEYNOTE-091, @ETOP_eu 8-15), a phase III study of adjuvant pembrolizumab in resected NSCLC. The study did meet its primary endpoint (DFS HR
KEYNOTE-091 - Adjuvant Therapy for Stage 1B (T2a ≥4 cm), Stage 2, or Stage 3A NSCLC Clinical Trial Results
PharmaShots. - • The P-III (KEYNOTE-091/EORTC-1416-LCG/ETOP-8-15 – PEARLS) trial evaluates Keytruda (200mg, IV, q3w) for 1yr. vs PBO in a ratio (1:1) in 1177 patients with stage IB to IIIA NSCLC following
癌免疫療法による周術期治療で呼吸器外科の治療体系は変わる(2ページ目)：日経メディカル
PEARLS/KEYNOTE-091: Pembrolizumab vs placebo in early-stage NSCLC
关于KeyNote-091研究的几点思考及疑惑|人群|患者|研究|错误|阴性|-健康界
Frühes nichtkleinzelliges Bronchialkarzinom: Pembrolizumab adjuvant nach Resektion verlängert das krankheitsfreie Überleben
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial - The Lancet Oncology
KEYNOTE-091研究一举成功，术后辅助NSCLC全人群DFS获益
Adjuvant Immunotherapy in Non–Small Cell Lung Cancer: Who Benefits?
